You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-expessing cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chordoma, Breast Cancer, Gastric/Gastroesophageal Junction Cancer Trial in United States (TAEK-VAC-HerBy)

Recruiting
  • Chordoma
  • +2 more
  • TAEK-VAC-HerBy
  • Scottsdale, Arizona
  • +8 more
Oct 27, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    HER2 Expression and Clinical Pathological Characteristics in

    Recruiting
    • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
    • Collect HER2 expression in prostate cancer patients
    • Jinan, Shandong, China
      Qilu hospital
    Nov 17, 2023

    Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Cessation of anti-HER2 treatment
    • Boston, Massachusetts
    • +1 more
    Feb 9, 2023

    HER2-positive Advanced Breast Cancer Patients Treated With ADC

    Recruiting
    • Breast Cancer
    • HER2 expression of circulating tumor cells
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Apr 18, 2023

    HER2-low Advanced Breast Cancer Patients Treated With ADC

    Recruiting
    • Breast Cancer
    • HER2 expression of circulating tumor cells
    • Beijing, Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Apr 18, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023

      HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

      Recruiting
      • HER2-positive Gastric Cancer
      • Immunotherapy
      • Disitamab Vedotin combined with fruquintinib and Tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 8, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

      Recruiting
      • HER2-positive Breast Cancer
      • Early-stage Breast Cancer
      • pyrotinib combined with Capecitabine
      • treatment of physician's choice
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 6, 2023

      HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

      Not yet recruiting
      • HER2 Low Breast Carcinoma
      • SHR-A1811 for injection
      • (no location specified)
      Jun 12, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

      Not yet recruiting
      • Breast Cancer Female
      • Pyrotinib and Trastuzumab
      • (no location specified)
      Sep 11, 2023

      DESTINY Breast Respond HER2-low Europe

      Not yet recruiting
      • Unresectable Breast Cancer
      • +2 more
      • Trastuzumab deruxtecan
      • (no location specified)
      Jul 6, 2023

      HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

      Not yet recruiting
      • HR+/HER2-breast Cancer
      • Standard endocrine therapy plus Apatinib
      • (no location specified)
      Jun 2, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023

      HER2-Positive Cancer Trial in Wuhan

      Active, not recruiting
      • HER2-Positive Cancer
        • Wuhan, Hubei, China
          TongjiHospital
        Sep 7, 2022

        Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

        Active, not recruiting
        • Hormone-receptor-positive Breast Cancer
        • +2 more
        • No drug
        • Cambridge, Massachusetts
          ConcertAI database
        Sep 8, 2023

        HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

        Not yet recruiting
        • HER2-positive Breast Cancer
        • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
        • (no location specified)
        Jul 20, 2023

        HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

        Not yet recruiting
        • HER2-positive Advanced Breast Cancer
        • (no location specified)
        Jun 4, 2023

        Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

        Recruiting
        • Gastric Cancer
        • HER2-low-expressing Gastric Cancer
        • Shanghai, China
          Shanghai East Hospital
        Oct 9, 2023

        Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

        Active, not recruiting
        • Breast Cancer
        • HER2-positive Breast Cancer
        • Zhengzhou, Henan, China
          Henan cancer hospital
        Jun 23, 2023